1255207-53-4

Upstream product

• 42044-81-5 4-hydroxy-5-methoxy-2-methylbenzaldehyde 
• 17763-80-3 para-nitrophenyl triflate 
• 1195-09-1 5-methyl-2-methoxyphenol 
• 4790-01-6 2-(benzyloxy)-1-methoxy-4-methylbenzene 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 

Downstream Products

• 1255207-54-5 4-formyl-2-methoxy-5-methylbenzonitrile 

Relevant academic research and scientific papers

PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to phenyl derivatives of formula (I) Formula (I) wherein (R1)n, R3, R4a, R4b, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure